ICI 105552

Subscribe to Selected New Research on ICI 105552

3 relevant articles (0 outcomes, 0 trials/studies) found for this Bio-Agent

Description: RN given refers to Na salt

Also Known As:

1-((3,4-dichlorobenzyl)-3-methyl)-1,2-dihydro-2-oxoquinol-4-ylacetate; 2,4-Cyclohexadien-1-one, 3-(acetyloxy)-6-((3,4-dichlorophenyl)methyl)-6-hydroxy-2-methyl-; I.C.I. 105552; ICI105552; 4-Quinolineacetic acid, 1-((3,4-dichlorophenyl)methyl)-1,2-dihydro-3-methyl-2-oxo-, sodium salt

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

2-Ring Heterocyclic Compounds

Quinolines: 58

Quinolones: 969

ICI 105552: 3

Related Diseases

1.	Body Weight (Weight, Body) 05/01/1983 - "Treatment with ICI 105552 produced small (less than or equal to 11%) yet statistically significant increases in the weights of the kidneys, and both liver and kidney weight/100 g residual body weight but did not affect the weights of the body, lens, retina or S.V.C.G" 11/01/1983 - "To test the possible involvement of the sorbitol pathway in the pathogenesis of retinopathy in long-term experimentally-diabetic rats, streptozotocin-diabetic and normal rats were dosed orally (50 mg/kg body weight daily) for up to 373 days with an aldose reductase inhibitor (ICI 105552) or a placebo" 05/01/1983 - "For 22 days, streptozotocin-diabetic and normal rats were intubated once daily with ICI 105552 (1-(3,4-dichlorobenzyl)-3-methyl-1,2-dihydro-2-oxoquinol-4-ylacetic acid, sodium salt: 50 mg/kg body weight) an inhibitor of aldose reductase (EC 1.1.1.21), the first enzyme of the sorbitol pathway" Get all the results and reference details, order at left...
2.	Diabetic Retinopathy (Retinopathy, Diabetic) 05/01/1983 - "The results: (1) demonstrated that ICI 105552 was a potent inhibitor of aldose reductase in sciatic nerve and suggested that a proportion of nerve lactate in diabetes could result from sorbitol pathway activity; (2) implied that flux through the sorbitol pathway, eventually to form lactate, increases in diabetic retina; and (3) indicated, by the drug's reduction of retinal lactate concentration, that inhibitors of aldose reductase might be of potential use in diabetic retinopathy." Get all the results and reference details, order at left...
2 Diseases and 3 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Sorbitol (Yal)
2.	Aldehyde Reductase (Aldose Reductase)
3.	Streptozocin (Streptozotocin)
4.	Lactic Acid
5.	Sodium
6.	Retinaldehyde (Retinal)
6 Drugs and Important Bio-Agents and 3 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>